Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag. KU Leuven
The promoters of this project have been active in combating cancers. They have pioneered research in tumor radiofrequency ablation (RFA) with a patent granted to K.U.Leuven, and also studied photodynamic therapy (PDT) and vascular targeting agents (VTAs) for experimental oncology. Despite encouraging results with RFA, PDT and VTAs to induce therapeutic tumor necrosis, sporadic or marginal residues are frequently attributed to tumor incomplete ...